Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MolecureWAR:MOC +0.33%27 EV-to-EBIT is -5.50 as of Aug. 11, 2026. GuruFocus rates WAR:MOC with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 372 Biotechnology companies, Molecure ranks worse than 268816.94% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Molecure's Enterprise Value is zł133.20 Mil.
Molecure's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was zł-24.21 Mil. Therefore, Molecure's EV-to-EBIT for today is -5.50.
The historical rank and industry rank for Molecure's EV-to-EBIT or its related term are showing as below:
WAR:MOC'
s EV-to-EBIT Range Over the Past 10 Years
Min: -5.5 Med: 1.93 Max: 9.97
Current: -5.5
During the past 11 years, the highest EV-to-EBIT of Molecure was 9.97. The lowest was -5.50. And the median was 1.93.
WAR:MOC's EV-to-EBIT is ranked worse than 100% of 372
companies
in the Biotechnology industry
Industry Median: 15.085
vs WAR:MOC: -5.50
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Molecure's Enterprise Value for the quarter that ended in Sep. 2025 was zł134.97 Mil.
Molecure's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-24.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecure EV-to-EBIT Related Terms
Molecure EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Molecure's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:MOC vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Molecure's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecure EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecure's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Molecure's EV-to-EBIT falls into.
Molecure's current Enterprise Value is zł133.20 Mil.
Molecure's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-24.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecure (WAR:MOC) has a EV-to-EBIT of -5.50 as of Aug. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Molecure and its competitors. According to the industry distribution chart, Molecure ranks #999999 out of 372 companies in the Biotechnology industry.
Is Molecure's EV-to-EBIT too high?
Molecure's current EV-to-EBIT is -5.50. Based on the distribution chart, Molecure ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Molecure has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Molecure's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecure ranks #999999 out of 372 companies for EV-to-EBIT. This places Molecure in the lower half of its industry. The industry median EV-to-EBIT is 15.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.09, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Molecure and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecure's current EV-to-EBIT is -5.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecure stock overvalued right now?
Molecure (WAR:MOC) has a current EV-to-EBIT of -5.50. The current EV-to-EBIT is -5.50. Molecure's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Molecure (WAR:MOC), the current EV-to-EBIT is -5.50 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.
27GF Score
Get the complete analysis for WAR:MOC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MOC has been successfully added to your 
